Functional polymers as therapeutic agents: Concept to market place

被引:66
作者
Dhal, Pradeep K. [1 ]
Polomoscanik, Steven C. [1 ]
Avila, Louis Z. [1 ]
Holmes-Farley, S. Randall [1 ]
Miller, Robert J. [1 ]
机构
[1] Genzyme Corp, Drug & Biomat R&D, Waltham, MA 02451 USA
关键词
Polymeric drugs; Biomaterials; Sequestrants; Local delivery; Non-absorbed therapy; MOLECULAR-WEIGHT HYALURONAN; BILE-ACID SEQUESTRANTS; CHRONIC KIDNEY-DISEASE; CLOSTRIDIUM-DIFFICILE; SEVELAMER HYDROCHLORIDE; MULTIVALENT LIGANDS; CLINICAL-PRACTICE; ANION RECEPTORS; CHOLESTEROL; DESIGN;
D O I
10.1016/j.addr.2009.05.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Biologically active synthetic polymers have received considerable scientific interest and attention in recent years for their potential as promising novel therapeutic agents to treat human diseases. Although a significant amount of research has been carried out involving polymer-linked drugs as targeted and sustained release drug delivery systems and prodrugs, examples on bioactive polymers that exhibit intrinsic therapeutic properties are relatively less. Several appealing characteristics of synthetic polymers including high molecular weight, molecular architecture, and controlled polydispersity can all be utilized to discover a new generation of therapies. For example, high molecular weight bioactive polymers can be restricted to gastrointestinal tract, where they can selectively recognize, bind, and remove target disease causing substances from the body. The appealing features of GI tract restriction and stability in biological environment render these polymeric drugs to be devoid of systemic toxicity that are generally associated with small molecule systemic drugs. The present article highlights recent developments in the rational design and synthesis of appropriate functional polymers that have resulted in a number of promising polymer based therapies and biomaterials, including some marketed products. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:1121 / 1130
页数:10
相关论文
共 88 条
[1]   Hyperphosphataemia in renal failure - Causes, consequences and current management [J].
Albaaj, F ;
Hutchison, AJ .
DRUGS, 2003, 63 (06) :577-596
[2]  
Alfonso I, 2001, HELV CHIM ACTA, V84, P280, DOI 10.1002/1522-2675(20010228)84:2<280::AID-HLCA280>3.3.CO
[3]  
2-F
[4]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[5]   The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure [J].
Amin, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) :340-345
[6]  
Avila LZ, 2008, CARBOHYDRATE CHEMISTRY, BIOLOGY AND MEDICAL APPLICATIONS, P333, DOI 10.1016/B978-0-08-054816-6.00015-X
[7]   Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: An overview [J].
Bailie, GR ;
Massry, SG .
PHARMACOTHERAPY, 2005, 25 (12) :1687-1707
[8]  
Bailie GR, 2004, FORMULARY, V39, P358
[9]   CLOSTRIDIUM-DIFFICILE - HISTORY OF ITS ROLE AS AN ENTERIC PATHOGEN AND THE CURRENT STATE OF KNOWLEDGE ABOUT THE ORGANISM [J].
BARTLETT, JG .
CLINICAL INFECTIOUS DISEASES, 1994, 18 :S265-S272
[10]   Viscosupplementation for the treatment of osteoarthritis of the knee [J].
Bellamy, N. ;
Campbell, J. ;
Robinson, V ;
Gee, T. ;
Bourne, R. ;
Wells, G. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02)